Search
Foslevodopa
go.drugbank.com/drugs/DB16683ApprovedFoslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants
Indapamide
go.drugbank.com/drugs/DB00808ApprovedInvestigationalagents may be required in order to achieve blood pressure targets. … [A204155] Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally.
Categories: Antihypertensive Agents Indicated for Hypertension, Cytochrome P-450 SubstratesStroke
go.drugbank.com/conditions/DBCOND0020609Drugs: Acetylsalicylic acid · Alirocumab · Apixaban · Atorvastatin · Cerebrolysin · Choline alfoscerate +14 moreEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigationalEnzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. … [A252667] Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like
Categories: Androgen Receptor Antagonists, Androgen Receptor InhibitorsFoscarbidopa
go.drugbank.com/drugs/DB16171ApprovedFoscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Adult
Fostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[L14867] The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically … orthogonal therapies) for the treatment of HIV-1 patients with resistant infections.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseIdelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalFor the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other … More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesNicorandil
go.drugbank.com/drugs/DB09220ApprovedInvestigationalWithdrawnIt is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs [T28]. … Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan.
Finasteride
go.drugbank.com/drugs/DB01216ApprovedInvestigationalFinasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or … the need for surgical procedures.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Ran-finasteride, Van-finasterideEsketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigationalThe intranasal route of administration for this drug allows for easy administration and a fast onset of action, which sets it apart from many other antidepressant agents that may take several weeks to … [L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications
Categories: Antidepressive Agents Indicated for Depression, NMDA Receptor Antagonists